Dickinson L C, Lee J, Ringdahl I C, Schedewie H K, Kilgore B S, Elders M J
J Pediatr. 1979 Apr;94(4):538-41. doi: 10.1016/s0022-3476(79)80006-2.
Decreased longitudinal growth was observed in 24 hyperkinetic children receiving pemoline therapy. Mean height velocity was 3.67 +/- 0.25 cm/year during therapy but 5.35 +/- 0.42 cm/year after treatment had been discontinued (P less than 0.01). There appeared to be an inverse relationship between growth velocity and drug dosage. All patients receiving less than the median dose of 3.72 mg/kg grew 4 cm/year or more, while seven of 12 patients receiving more than this dose grew at a slower rate. Body weight, basal and stimulated growth hormone values, and plasma somatomedin concentrations were not significantly altered by pemoline treatment, suggesting that this drug may have a direct effect on cartilage metabolism.
在接受匹莫林治疗的24名多动症儿童中观察到纵向生长减缓。治疗期间平均身高增长速度为3.67±0.25厘米/年，但停药后为5.35±0.42厘米/年（P<0.01）。生长速度与药物剂量之间似乎存在反比关系。所有接受低于中位数剂量3.72毫克/千克的患者每年生长4厘米或更多，而接受超过此剂量的12名患者中有7名生长速度较慢。匹莫林治疗对体重、基础和刺激后的生长激素值以及血浆生长调节素浓度没有显著影响，表明该药物可能对软骨代谢有直接作用。
